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Abstract 
Objectives 
The duration and the frequency of follow-up after treatment of oral squamous cell carcinoma are not 
standardized in the current literature. The purpose of this study was to evaluate our local standard post-
treatment and follow-up protocol. 
Materials and methods 
Overall, 228 patients treated curatively from 01/2006 to 07/2013 were reviewed. To evaluate the follow-up 
program, data on the secondary event were used. To determine risk groups, all patients with tumor recurrence 
were specifically analyzed. Relapse-free rate were estimated by the Kaplan-Meier product limit method. The chi-
square test was used to identify independent risk factors for tumor relapse. 
Results 
In total, 29.8 % patients had a secondary event. The majority of the relapse cases (88.2 %) were detected within 
2 years postoperatively, 61.8 % of them within the first year. Most events were local recurrences (34.7 %). UICC-
stage IV was significantly associated with tumor recurrence (p = 0.001). Gender (p = 0.188), age (p = 0.195), 
localization (p = 0.739), T-stage (p = 0.35), N-stage (p = 0.55), histologic grade (p = 0.162), and tobacco and 
alcohol use (p = 0.248) were not significantly associated with tumor recurrence. Patients with positive neck 
nodes relapsed earlier (p = 0.011). The majority of relapses (86.3 %) were found in asymptomatic patients at 
routine follow-up. 
Conclusions 
The results of this study suggest an intensified follow-up within the first 2 years after surgery. 
Clinical relevance 
Given the higher relapse rate of patients exhibiting an UICC-stage IV and/or positive neck nodes, it seems to be 
from special interest to perform in this group a risk-adapted follow-up with monthly examinations also in the 
second year. 
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Introduction 
Oral squamous cell carcinoma (OSCC) is the most common malignant tumor of the mouth. Worldwide, its 
estimated incidence is around 275,000 cases per year [1]. Despite great progress in surgery and adjuvant radio- 
and chemotherapy in the last decades, the prognosis of OSCC is still poor with a 5-year survival rate at about 50 
to 55 % [2]. Main reason besides the aggressive local invasion and metastasis is tumor relapse. A recurrence rate 
from 35.5 to 47.1 % has been reported [3, 4]. 
For an early detection of recurrences and to offer the patient a promptly second curative therapy, a post-
treatment follow-up protocol is indispensable for these patients. Some authors argue that too much follow-up is 
costly and labor intensive [5, 6, 7], while others believe that a reduction in the follow-up period is irresponsible 
due to a high risk of tumor relapse [8, 9]. 
The purpose of this presented study was to evaluate our local standard treatment and follow-up protocol in 
patients with oral squamous cell carcinoma and to identify risk groups for tumor recurrence. 
Materials and methods 
All patients included signed consent for the evaluation of their medical records. The medical records of 228 
patients with histological confirmed diagnoses of OSCC who underwent surgery at the Jena University Hospital 
from 01/2006 to 07/2013 with curative intent without previous malignancy were reviewed. The follow-up 
program was started after completion of adjuvant radiotherapy or combined radio-chemotherapy, if necessary, 
and postoperative rehabilitation. To determine risk groups, all patients with tumor recurrence were specifically 
analyzed. 
Surgical regimen and clinical classification 
All patients underwent curative resection of OSCC. Neck dissection was routinely performed in all patients. 
Resection specimens were pathologically diagnosed using primary and neck dissection tissues. Tumor stage was 
classified according to the TNM classification of the International Union against Cancer (UICC) [10]. Tumor size 
(T), lymph node metastasis (N), and distant metastasis (M) were staged based on clinical and histopathologic 
findings in addition to images from computed tomography (CT), ultrasonography (USG), and chest x-ray 
examination. Tumor histological grade (G) was defined according to the WHO classification. 
Follow-up program 
Routine follow-up included monthly clinical examinations in the first year, trimonthly examinations in the 
second year, and biannual examinations thereafter for up to the end of fifth year. After the fifth postoperative 
year, only high risk patients were still examined biannually. Each visit included a short medical history, 
inspection and palpation of the oral cavity, palpation, and a routine USG of the head and neck region. Routine 
CT with contrast agent was performed after 6, 12, and 24 months, postoperatively. Chest x-ray was taken every 
12 and 24 months after treatment to detect lung metastasis. USG of abdomen were performed after 12 and 
24 months. In addition, CT, chest x-ray and USG of abdomen were performed after 36, 48, and 60 months in 
patients with T > 2 and/or positive neck nodes and/or M = 1 and/or R > 0 and/or G > 2. 
Secondary event 
A secondary event was defined as local recurrence, regional recurrence, locoregional recurrence, distant 
metastasis, or a second primary tumor. Local recurrence was defined as tumor growth at the same location 
within a period of 5 years after primary treatment with curative intent. Tumor growth at a different site in the 
aerodigestive tract or at the same location in the oral cavity more than 5 years was considered as second 
primary tumor. Regional recurrence was defined as tumor regrowth in lymph nodes of the neck and locoregional 
recurrence as tumor regrowth at the same location in combination with regrowth in lymph nodes of the head 
and neck. Distant metastasis was defined as tumor spread from the aerodigestive tract to distant organs or 
distant lymph nodes outside the head and neck region. 
Statistical analysis 
To evaluate the follow-up program, data on the first tumor recurrence or first second primary tumor and also 
further events in the head and neck region or elsewhere in the body were used. Statistical analyses were 
performed using SPSS 21.0 for Windows (Chicago, IL). Relapse-free rate for patients with secondary event were 
estimated by the Kaplan-Meier product limit method. Relapse-free rates were calculated with local recurrences, 
regional recurrences, locoregional recurrences, distant metastases, and second primary tumors. Statistical 
significance was compared using the log-rank test. Chi-square test was used to identify independent risk factors 
for tumor recurrence. P < 0.05 was considered statistically significant. 
Results 
Patient characteristics are summarized in Table 1. In total, 228 patients were included: 177 men (78 %) and 51 
women (22 %) with median age of 58 years. Mean age of 60 years ranged from 24 to 89 years at the time of 
surgery. The most prevalent site of tumor localization was the floor of mouth in 90 patients (39.5 %), followed 
by tongue in 50 patients (21.9 %), multiple areas in 28 (12.3 %), lower jaw in 19 patients (8.3 %), retromolar 
region in 13 patients (5.7 %), upper jaw in 10 patients (4.4 %), buccal mucosa in 9 patients (3.9 %), and soft 
palate in 9 patients (3.9 %). One hundred seventy-six patients (77.2 %) underwent follow-up visits strictly 
according to protocol. Twenty-six patients (11.4 %) participated irregularly, and further 26 patients (11.4 %) did 
not take part in the follow-up program or shown up at other hospitals. 
Table 1 Patient characteristics and appearance of a secondary event 
Characteristics No. of patients (%) No. of patients with a secondary event (%) p value 
All patients 228 (100) 68 (100)   
Gender     0.188 
 Male 177 (77.6) 49 (72.1)   
 Female 51 (22.4) 19 (27.9)   
Age     0.195 
 ≤49 39 (17.1) 15 (22.1)   
 ≥50 189 (82.9) 53 (77.9)   
Site     0.739 
 Oral floor 90 (39.5) 31 (45.6)   
 Tongue 50 (21.9) 14 (20.6)   
 Lower jaw 19 (8.3) 6(8.8)   
 Retromolar region 13 (5.7) 5 (7.4)   
 Upper jaw 10 (4.4) 1 (1.5)   
 Buccal mucosa 9 (3.9) 2 (2.9)   
 Soft palate 9 (3.9) 3 (4.4)   
 Multiple areas 28 (12.3) 6 (8.8)   
T-stage     0.35 
 T1 75 (32.9) 28 (41.2)   
 T2 82 (36.0) 20 (29.4)   
 T3 22 (9.6) 6 (8.8)   
 T4 49 (21.5) 14 (20.6)   
N-stage     0.55 
 N- 134 (58.8) 41 (60.3)   
 N+ 94 (41.2) 27 (39.7)   
UICC-stage     0.001 
 I 63 (27.6) 15 (22.1)   
 II 49 (21.5) 8 (11.8)   
 III 30 (13.2) 6 (8.8)   
 IV 86 (37.7) 39 (57.4)   
Histologic grade     0.162 
 Well 24 (10.5) 5 (7.4)   
 Moderately 145 (63.6) 40 (58.8)   
 Poorly 59 (25.9) 23 (33.8)   
Risk factors     0.248 
 Alcohol 6 (2.6) 1 (1.5)   
 Tobacco 66 (28.9) 14 (20.6)   
 Alcohol and tobacco 95 (41.7) 32 (47.1)   
 No risk factors 61 (26.8) 21 (30.8)   
N+ positive neck nodes, N− negative neck nodes 
Tumor relapse 
Sixty-eight of 228 patients (29.8 %) had a secondary event. After the secondary event, further 27 events were 
found in these patients during follow-up. The largest proportion of all events consisted of local recurrences. 
Thirty-three of these 95 events (34.7 %) were local recurrences. Distant metastases and regional recurrences 
were detected in 21 events (22.1 %) and 19 events (20.0 %), respectively. Further 12 events (12.6 %) were 
locoregional recurrences and 10 events (10.5 %) second primary tumors (Table 2). Forty-two secondary events 
(61.8 %) were detected within 1 year, and sixty events (88.2 %) were detected within 2 years. The mean interval 
between surgery and secondary events was 13 months (range, 1 to 53 months), and the median interval was 
10 months, suggesting that 50 % of these events were detected in the first 10 months of follow-up program. 
Table 2 Detecting recurrence in the follow-up 
  Site of 
recurrence 
    
 
Local (%) Regional 
(%) 
Loco-regional 
(%) 
Second 
primary (%) 
Distant 
metastasis (%) 
Routine follow-up visit 
(n = 82) 
          
Clinical examination 
(n = 41) 
16 (48.5) 7 (36.8) 7 (58.3) 4 (40.0) 7 (33.3) 
Radiological 
examinations (n = 31) 
11 (33.3) 6 (31.6) 3 (25.0) 4 (40.0) 7 (33.3) 
Ultrasound examinations 
(n = 10) 
0 6 (31.6) 1 (8.3) 0 3 (14.3) 
Self-initiated visit (n = 13) 6 (18.2) 0 1 (8.3) 2 (20.0) 4 (19.0) 
Total (n = 95) 33 (100) 19 (100) 12 (100) 10 (100) 21 (100) 
Chi-square test revealed that stage IV was significantly associated with tumor recurrence (p = 0.001). In contrast, 
gender (p = 0.188), age (p = 0.195), localization (p = 0.739), T-stage (p = 0.35), N-stage (p = 0.55), histologic grade 
(p = 0.162), and tobacco and alcohol use (p = 0.248) were not significantly associated with tumor recurrence. 
 
All patients with tumor recurrence were specifically analyzed to determine risk groups. Relapse-free rate for 
patients with secondary event were estimated by Kaplan-Meier product limit method. No statistically significant 
differences could be found between patients with different T-stage (p = 0.3), UICC-stage (p = 0.09), histological 
grade (p = 0.507), gender (p = 0.738), localization (p = 0.7) and with risk factors tobacco and alcohol use 
(p = 0.369). However, there was a statistically significant difference between patients with negative neck nodes 
and those with positive neck nodes (p = 0.011). Patients with pathologically diagnosed positive neck nodes in the 
primary operation relapsed earlier. In addition, all patients with tumor recurrence and pathologically diagnosed 
positive neck nodes in the primary operation were detected within 20 months (Fig. 1). 
 
Fig 1 Recurrence-free rate in patients with secondary event by node classification: positive neck nodes 
(N+; green line) and negative neck nodes (N-; blue line) 
 
Tumor relapse detected on routine follow-up 
Tumor relapse was discovered during a patient-initiated visit for complaints in 13 (13.7 %) events and was found 
during a routine follow-up visit in 82 (86.3 %) cases. Overall, 41 (43.2 %) events were identified clinically, 31 
(32.6 %) were detected by routine radiological examination and further 10 (10.5 %) by USG. In total, radiological 
examination detected 11 occult local recurrences, 6 regional recurrences, 3 locoregional recurrences, 4 second 
primary tumors, and 7 distant metastases. USG identified 6 regional recurrences, 1 locoregional recurrence and 
3 distant metastases. In the patient-initiated group, the most common site was local recurrence (6 cases). 
(Table 2). 
Discussion 
The optimal post-treatment follow-up strategy for patients with OCCC was not yet described in the current 
literature. The majority of reported follow-up programs were site-specific or applicable to all head and neck sub-
sites. Furthermore, follow-up strategies vary substantially among specialized centers. The number of visits 
ranges from a minimum of 9 visits over 3 years [11] to a maximum of 48 visits over 5 years [12]. Various 
accepted international guidelines for follow-up treatment protocols are listed in Table 3 [13, 14, 15]. 
Table 3 International guidelines for follow-up treatment protocols 
  Post-treatment year Follow-up strategy Imaging 
AWMF [13], Germany First year Every 3 months Every 6 months  
Second year Every 3 months Every 6 months  
Third year Every 6 months Every 12 months  
Fourth year Every 6 months Every 12 months  
Fifth year Every 6 months Every 12 months  
>Fifth year Routine screening – 
NCCN [14], 
United States of America 
First year Every 1–3 months Within 6 monthsa 
 
Second year Every 2–6 months –  
Third year Every 4–8 months –  
Fourth year Every 4–8 months –  
Fifth year Every 4–8 months – 
 
>Fifth year Every 12 months – 
BAHNO [15], 
Great Britain 
First year Every 4–6 weeks Within 3 months 
 
Second year Every 4–6 weeks –  
Third year Every 3 months –  
Fourth year Every 6 months –  
Fifth year Every 6 months –  
>Fifth year Every 12 months – 
AWMF Association of Scientific Medical Societies in Germany, NCCN National Comprehensive Cancer 
Network, BAHNO British Association of Head and Neck Oncologists 
aImaging is recommended for T3-4 or N2-3 disease only 
 
In our institute, all patients with OSCC are followed according to the evidence-based guideline for oral cavity 
cancer organized under the aegis of the Association of Scientific Medical Societies in Germany (AWMF). This 
guideline involves an interval between follow-up visits every 3rd month in the first 2 years and every 6 months 
in year 3 to 5. After the completed 5th year, patients should attend routine tumor screening [13]. We strictly 
follow this guideline, with the only exception that we perform a more frequent follow-up with monthly 
examinations in the first year. The structure of this follow-up program is designed to identify early recurrences, 
which is known to be more frequent in the first 2 years after completion of primary treatment [16]. 
Comprehensive Cancer Network (NCCN) guidelines scheduled follow-up visits, every 1 to 3 months for the first 
year, every 2 to 6 months for the second year, every 4 to 8 months for the third to fifth years, and then annually 
[14]. Additionally, British Association of Head and Neck Oncologists (BAHNO) recommend clinical examinations 
every 4–6 weeks during the first and the second year after primary therapy, every 3 months for year 3, every 
6 months for years 4–5, and annually thereafter [15]. 
In this presented study, 61.8 % of the secondary events occurred within the first year, 88.2 % within 2 years, and 
all events were detected within 5 years. These results could require a stricter follow-up for locoregional control 
within the first 2 years after surgery and confirmed our monthly visit program during the first year. One point to 
think about is if patients should be seen more frequently in the second year with monthly or bimonthly 
examinations. In addition, tumor recurrence was discovered during a patient-initiated visit for complaints only in 
13 (13.7 %) events and was detected during a routine follow-up visit in 82 (86.3 %) cases. This confirms the 
importance of a routine follow-up and endorses our strategy. 
Overall, 29.8 % of the analyzed patients had recurrences. This is fewer yet comparable to the literature, with 
recurrence rates varying between 35.5 and 47.1 % [3, 4]. The most frequent form of relapses was local 
recurrences which accounted for 34.7 % of all cases. Chi-square test and log-rank test showed that UICC-stage IV 
was important factor of tumor recurrence (p = 0.001) and that pathologically diagnosed positive neck nodes 
predict earlier relapse (p = 0.011). All patients with tumor recurrence and pathologically diagnosed positive neck 
nodes in the primary operation relapsed within 20 months. Maybe, it seems to be suitable to classify patients 
with UICC stage IV and/or positive neck nodes as high risk group for tumor recurrence. More frequent follow-up 
visits with monthly examinations in the second year could be necessary in these patients. 
However, the benefit in cancer survival with routine follow-up has not been well proven in the current 
literature. Studies have not been conclusive with respect to survival, in the physician-detected recurrent disease 
versus patient-detected [17, 18]. Therefore, several references consider that regular follow-up program does 
not have any influence on survival outcomes [18, 19, 20]. 
Due to the anatomical and functional alterations after operation, post-treatment surveillance for the recurrence 
or distant metastasis of OSCC is a diagnostic challenge. In this presented study, 41 (43.2 %) events were 
identified clinically. However, clinical examination alone is not sufficient to detect tumor recurrences. Imaging 
modalities such as USG, chest x-ray, and CT can provide key information for the adequate stages of patients and 
evaluation of occult recurrences. In all, 31 events (32.6 %) were detected by routine radiological examination 
and further 10 (10.5 %) by USG in this study. 
In our institute, the follow-up program was performed by the same physicians. Therefore, scrupulous head and 
neck examinations were realized. In addition to inspection and palpation of the oral cavity, and palpation of the 
neck, routine USG was used. We think that combination of clinical examination and USG is valuable in detecting 
regional recurrence early. USG findings of cervical lymph node metastasis were shown to change as quickly as 
within 2 to 4 weeks [12]. Because of its advantages of simplicity, its lack of radiation exposure and lower costs, 
USG should be routinely performed at each visit. In all, USG had importance for detection of 6 regional 
recurrences, 3 distant metastases, and 1 locoregional recurrence. 
AWMF recommends CT scan of the head and neck region every 6 months in the first 2 years after treatment and 
every 12 months for the third to fifth years [13]. In the current study, routine CT was used after 6, 12, and 
24 months postoperatively. Only in patients with T > 2 and/or positive neck nodes and/or M = 0 and/or R > 0 
and/or G > 2 CT (besides chest x-ray and USG of abdomen) was performed after 36, 48, and 60 months. Above 
all, radiological examinations were beneficial in detecting occult local recurrences (11 cases), regional 
recurrences (6 cases), locoregional recurrences (3 cases), second primary tumors (4 cases), and distant 
metastases (7 cases). In contrast, other international guidelines are not recommending post-treatment baseline 
imaging at regular intervals. NCCN suggests a radiological examination within 6 months for patients with T-stage 
3–4 or N-stage 2–3. Further imaging investigation are based only on symptoms or signs [14]. In addition, BAHNO 
recommends imaging examination 3 months after completion of treatment [15]. There are indications in the 
literature that radiological examinations at regular intervals provide no advantage over improvement of patient 
outcomes [21]. However, radiological examination can detect recurrence at an early stage in order to provide 
salvage procedures with curative intent. 
In the present study, we used CT with contrast agent and chest X-rays to detect occult recurrences such as 
second primary tumors and distant metastases. Further imaging modalities are magnetic resonance (MR) 
imaging and 18-F-fluorodeoxyglucose positron emission tomography (18-FFDG-PET). The advantage of MR over 
CT is a better soft-tissue differentiation [22]. In contrast, CT has lower cost than MR, a shorter examination time 
with reduction of motion artifacts. 
There are indications that 18-FFDG-PET has a better accuracy in recurrence detection of head and neck cancer 
than with CT and/or MR [23], but it is not available in all hospitals and is more cost intensive. Generally, the 
baseline imaging exam should be the same that has been performed in the pretreatment staging [24]. 
Conclusion 
The results of this study suggest an intensified follow-up within the first 2 years after surgery, e.g., in a monthly 
interval. Imaging examinations are useful to detect occur recurrence and should be performed at regular 
intervals. Given the higher relapse rate of patients exhibiting an UICC-stage IV and/or positive neck nodes, it 
seems to be from special interest to perform in this group a risk-adapted follow-up with monthly examinations 
also in the second year. 
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